About James La Rossa

This author has not yet filled in any details.
So far James La Rossa has created 119 blog entries.

MDMA-Assisted Psychotherapy Improves PTSD

By |2018-06-05T15:12:24+00:00June 5th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies show. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2018 annual meeting. The pooled data from the [...]

Letter to the Editor: The Utilization of Atypical Antipsychotics in the Pain Medicine Physician’s Armamentarium

By |2018-06-08T16:47:30+00:00June 5th, 2018|Uncategorized|

By Omar Viswanath MD Dear Editor, I read with great interest the recent article by Jimenez et al, A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine. The article states “many psychopharmacologic agents are used as primary or adjuncts in pain [...]

An Alzheimer’s Antibiotic Receives Initial Funding

By |2018-06-01T09:11:54+00:00June 1st, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according to a posting today on FierceBiotech. The healthy sum comes after the company completed an early safety study of its [...]

Three-year Naturalistic Study On Early Use Of Long-acting Injectable Antipsychotics In First Episode Psychosis

By |2018-06-08T16:47:33+00:00May 24th, 2018|Uncategorized|

By Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, and Stéphane Potvin Abstract Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psy- chosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these stud- ies represent a minority of patients [...]

An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature

By |2018-06-08T16:48:07+00:00May 24th, 2018|Uncategorized|

By Marcela Almeida and Heather Burrell-Ward To the editor, We read with great interest the article by S. Thippaiah and colleagues in a recent issue of the journal. The authors reported the interesting case of a 19-year-old woman who presented with cyclical changes in mood and behavior, alternating between depression and [...]

A Review of Clinical Literature: Stimulants, Insomnia and Psychiatric Comorbidity in Veterans

By |2018-05-11T16:26:32+00:00May 11th, 2018|We Know Psychiatry|

Prescription Stimulant Use, Misuse, and Motivations Approximately 16 million US adults used prescription stimulants in the preceding year (annual average), 5 million misused prescription stimulants without use disorders, and 0.4 million had use disorders, according to a recent study. Researchers conducted a nationally representative household population study of adults aged [...]

News From the APA Convocation: Antipsychotics, Opioids, and PTSD

By |2018-05-09T13:04:15+00:00May 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Study Shows Continued Use of Certain Antipsychotics During Pregnancy May Increase Risk of Gestational Diabetes New York, NY. Women who take certain antipsychotic medications and continue the use of these medications through pregnancy may be at increased risk for gestational diabetes, according to new research published online today by the American Journal of [...]

Efficacy of Vortioxetine in Working Patients with GAD

By |2018-06-01T15:19:29+00:00May 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Background Vortioxetine is an approved antidepressant that has also demonstrated positive effects on anxiety symptoms in subjects with generalized anxiety disorder (GAD). This post-hoc analysis evaluates the efficacy of vortioxetine in GAD subjects who are working and/or pursuing an education. Methods In study NCT00744627, 301 GAD subjects were randomized to [...]

Latest Research on Cannabis and Cannabidiols: Autism, Stress Anxiety and Depression

By |2018-05-11T13:53:42+00:00April 30th, 2018|Featured, We Know Psychiatry|

Autism Researchers at University of California San Diego School of Medicine are preparing a first-of-its-kind, multidisciplinary investigation to determine if and how cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, provides therapeutic benefit to children with severe symptoms of autism spectrum disorder (ASD). The study, scheduled to launch [...]

A Case Of Hyper Sexuality Associated With Clozapine

By |2018-06-08T16:48:14+00:00April 20th, 2018|Uncategorized|

By Sereen Rose Thomson, Navin Patil, Balaji Ommurugan, and Rajesh Krishna Bhandary Abstract Schizophrenia treatment needs to cover several psychological interventions and pharmacological treatment for stabilizing the disease course and decreasing relapses. Sexual side effects are a major hindrance to patients and lead to decreased adherence to therapy and reduced quality of life. Recently, [...]